PROTEINE RESOURCES
The Pet Health & Longevity Company
Making longevity manufacturable. Starting with the bowl.
They give us their whole life.
We want to give back even more. Not just time, but health too.
Pets might live longer, but they don't live healthier
We know which compounds extend healthy life. We cannot deliver them. As purified extracts they cost like medicine, absorb poorly, and cannot be fed twice a day.
We grow them inside living tissue, at the cost of ordinary feed. Pet food first: the fastest route from ground to shelf.
Kealy et al., J Am Vet Med Assoc 220:1315, 2002.
from diet
Medicine added the years. Nobody added the health.
Segment proportions illustrative. Only the +1.8 yr figure is measured.
There's nothing to build from.
Function or price. And the gap between them widens every year.
What one 400 g can costs today
Fresh meat plus purchased additives. 30% inclusion, at scale.
Only one of these numbers moves. US cattle herd: smallest since 1951, no rebuild before 2028. EU beef at record levels. Feed grain down 14%. We buy on the falling curve.
Buy the pieces separately and you pay specialty prices for each one, stripped of the structure that made it absorbable.
Ames, PNAS 115:10836, 2018. Beelman et al., J Nutr Sci 9:e52, 2020. Positions illustrative, prices published.
The mushroom carries the compounds. The insect makes them edible for a carnivore.
Insulin is grown in bacteria. Nobody calls it bacterial insulin.
They said you couldn't grow mushroom compounds inside animal tissue at feed prices.
01 · The source
Spent mushroom substrate
Ergothioneine, ergosterol, the fungal fraction. A mushroom-farming waste stream, plus one proprietary ingredient.
02 · The converter
Alphitobius diaperinus
Turns fungal compounds into animal tissue. Five-week cycle, no light, built for automation.
03 · The control
Seven years of process
AI-controlled climate and density, multispectral vision. In no patent, and not for sale.
The output
A wet functional matrix
Never dried. Straight into a wet recipe, compounds carried in tissue a carnivore will actually eat.
The process is a dial, not a fixed output.
We design the profile before we grow it. Protein availability, the structural fraction and the fibre to ash and protein to fat balance are all set during cultivation.
Balanced profile for everyday wet food. Predictable structure, favourable fermentation, SCFA about 11.8× BCFA.
High-digestibility profile for high inclusion and gut health products. Protein digestibility to approximately 80% in vitro.
New SKUs come from the same biology, the same plant and the same database.
Every part of this is different
That industry
Us
Sold the insect as protein, competing on price with soy
We sell function that has no substitute
Fed cheap waste to make cheap protein
We feed mushroom substrate to make compounds nobody else has
Built factories before demand existed
Product on the shelf before the plant was finished
Dried, defatted meal for extrusion
Natively wet, for wet food
For them, the insect was the product. For us, it is the process.
What's actually in it: EntoPro™
One ingredient. One analysis. Nothing added, nothing extracted.
EUR 0.30
We do the same can for this.
Around 20% less, from one ingredient instead of six.
Ergothioneine
the "longevity vitamin"
We grow it in.
Longevity research's headline compound. Food is the only source, and the body has a dedicated system to store it where cells are under stress. Levels fall with age. Low levels track frailty and decline. Meat carries none.
~2×
the chitin of insect protein
Prebiotic potential, none added
60%+
protein, dry matter
Every essential amino acid present
1.87×
higher protein digestibility
Up to ~80% in vitro, in the high-digestibility profile
~63%
unsaturated fatty acids
Led by oleic and linoleic
B + Zn
vitamins & trace minerals
Naturally incorporated
0
contaminant flags
Within or below every EU limit
+30% SCFA
Short-chain fatty acids, the metabolites that indicate microbiota activity. SCFA run about 11.8× higher than BCFA, so fermentation favours the beneficial pathway.
One matrix, matched to every stage of life
Growth
Complete amino acids, plus structure
Adult years
Natural fats. Skin, coat, condition
Digestive resilience
Chitin-fibre fraction, measured fermentation activity
Ageing
Ergothioneine and ergosterol. Cellular protection
Sensitivity, at any age
One protein the animal has never eaten before
Measured in the lab. Now being proven in the animal.
One matrix. Every category it can reach.
One organism, one cultivation process, one input stream
VELI wet food range
The current SKUs, as they actually look
Supplements
Gut health and oxidative stress. The two clearest functional stories.
Air-dried formats
Derived from the same wet base
IPC, IPI, IPH concentrates, isolates and hydrolysates extend margin without a second biological platform. Project decision follows the expert panel in September 2026.
NEXITOSAN: pharmaceutical-grade chitosan
The same cultivation protocol raises the chitin fraction about 2.15× above the base profile. From it we produce chitosan at biomaterial grade.
- Over 90% chitosan content with a high degree of deacetylation
- 10× lower ash than marine chitosan, no demineralisation step
- Microplastic free independently confirmed by SGS Poland
Target applications: drug delivery, controlled release, mucoadhesive systems, wound dressings, haemostatics.
Functionality report in wound dressings due end of Q3 2026.
40+ potential applications assessed, across animal and human use. Pet food first: lowest regulatory barrier, fastest route to shelf.
In-vivo validation with UR Kraków is the gate. If it confirms what the biology predicts, the same platform points at markets orders of magnitude larger.
Pet food is the beachhead. Healthspan is the business.
We sell ingredients and finished recipes to pet food brands.
VELI is how we prove them, not how we grow.
01 · EntoPro ingredient
Sold to pet food manufacturers at EUR 2.50/kg.
Feed material 009841-EN. Authorised in the EU and Canada.
Amino acids, lipids, B vitamins, choline, zinc and iron are naturally present, so a finished recipe needs less synthetic supplementation. That lowers total formulation cost, not just the protein line.
Core revenue stream
02 · Finished recipes and private label
Complete, market-tested formulations under a partner's brand.
The customer skips formulation, palatability testing and consumer validation. We have already done all three.
Highest value per tonne
03 · VELI, our own brand
Poland only. Direct to consumer.
Six wet SKUs live, selling, with returning customers.
Our test bed and reference, not our growth engine
Why the recipes matter more than the ingredient.
A brand buying a novel ingredient normally faces two years of formulation, palatability work and consumer risk. We hand them a recipe that already sells. That is why we built VELI: to stand in our customer's shoes before asking them to stand in ours.
First order in negotiation: 100,000 cans for 2027.
Four locks. Three of them can't be bought.
Everyone can see the destination. Almost nobody can get there.
Legal
5+ patents covering the core technology
Protects the process, not just the product
Regulatory
EU novel food (2023), Canada listed (2026), US next
Over three years elapsed; a competitor starts at zero
Economic
Waste-stream substrate; natively wet output, no drying step
Cost floor decoupled from commodity markets
Biological
Functional compounds carried in native animal tissue
Nothing comparable exists at feed-level cost
Underneath all four: seven years of R&D and internal know-how. Not patentable, not licensable, not hireable at speed.
Anyone can copy a formula. Nobody copies seven years.
Pets are becoming the children
Not a metaphor. A measurable shift in how households spend.
Europe
+270%
growth in UK pet care spending since tracking began in 2005.
64% of Europeans say they treat their pet as a child.
North America
87M
US homes have a pet. More households have pets than children under 18.
Annual spend per dog has doubled in a decade, from about $1,200 to $2,400.
Asia
57%
of stroller sales in South Korea are now pet strollers, not baby strollers.
Up from 33% in 2021. In Japan, cats and dogs outnumber children under 15.
$165B in the US. $132B across Asia Pacific by 2027. Rising in every market we sell into.
When a pet becomes a child, the spending model changes with it.
Not premium food. Prevention, supplements, longevity. A market that buys mechanism, not narrative.
The regulator is legitimising the category, at someone else's expense.
Loyal has cleared two of three FDA sections for a canine lifespan drug: a ten-year-old dog, by prescription, at USD 40-90 a month. The bowl reaches every dog from month three.
We sell a finished product.
Under our brand and under theirs.
What a partner receives
A finished, market-tested recipe.
Regulatory documentation for the EU and Canada. Specification, palatability data and label support.
What they skip
Formulation. Palatability trials. Consumer validation.
Two years of development risk.
How it runs here
VELI: proof, not intention
Selling, with customers returning.
Private label
The same recipes under a partner's brand.
Pipeline & markets
More wet recipes and supplements. Poland: VELI only.
The same tonne, monetised five times.
€0.5/kg
what it costs us to make, at 3,000 t / year
NEXITOSAN is pharmaceutical-grade chitosan sold at veterinary prices. Same tonne, different industry.
Product on the shelf before the plant. Demand first, capital second. The plant is sized to a market we already sell into.
Revenue per tonne, indexed
Indicative, relative values
Raw material
feed pricing
Private label food
Own-brand food
brand pricing
Supplements
NEXITOSAN
pharmaceutical pricing
capex, flat
At 100 t / year and EUR 2.50/kg, ingredient sales alone are worth EUR 250,000. The same tonnage sold as finished recipes is worth several times that. This is why we sell product, not powder.
It's not a plan. It's already happening.
Funded
€12M secured. Most of it still ahead of us.
Drawn to date
~€1M of the €2.5M EIC grant, plus the Radix round.
In disbursement
The rest of the grant, over 15 months.
Committed forward
€7M EIC Fund: 50% of our Series A in 2027.
It built the plant, the patents, the EU and Canada approvals and six products on a shelf. 9th Polish EIC winner ever.
Building
Autonomous plant rising, Olkusz
100% of output feeds our own recipes and trials
VELI live: 6 SKUs, selling
Three gates cleared. The last one is the whole thesis.
1. In vitro cleared
digestibility confirmed
2. Palatability cleared
accepted, even by cats
3. Scale economics cleared
€0.5/kg at 3,000 t/yr. The gate most ingredient companies never clear
4. In vivo in progress
health & longevity readout with UR Kraków. The last mile
In vitro already confirms the direction. Even a neutral readout leaves a high-value protein at a better price, with approvals, patents and a brand selling. In vivo is upside, not foundation.
What lands, and when
Q3 2026
NEXITOSAN functionality report in wound dressings
Sep 2026
Expert panel decision on IPC, IPI and IPH
Q4 2026
NEXITOSAN publication
Q4 2026
3 to 5 publications on functional modification in EntoPro
31 Dec 2026
In vivo complete: broad cohort of dogs and cats, plus the healthy ageing readout
One closed loop. Nothing wasted.
Ten tonnes today. One hundred from Q1 2027.
EntoPro capacity
10 t / year
Output
100% goes to our own recipes and trials
VELI
6 SKUs live, direct to consumer
Plant
Under construction in Olkusz
EntoPro capacity
100 t / year
Step change
Tenfold increase, plant complete
Commercial
First B2B volume orders served
First order
100,000 cans for 2027 with a European premium brand
Volume
That order alone consumes 12 tonnes of EntoPro
12% of our 2027 capacity, from one customer
The capacity step is what makes B2B volume possible. Until Q1 2027 we can prove the product but not supply it at scale.
First reactions are in, and they're loud.
200+
real consumers tested VELI
99%
super positive reactions
100%
controlled palatability tests confirmed
“Piorun dragged the bowl across the living room. That's how clean he licked it.”
Sabina & Piorun · 5★
“He fell in love with both flavours from the first bite.”
Żaneta & Bafi · 5★
“He licked the bowl clean every time. Zero digestive trouble.”
Józef & Azor · 5★
“I can see his gut working better. Clean results.”
Artur & Frodo · 5★
Two risks, met by the right people.
A founder who has built and exited deep-tech. An inventor who spent six years on the biology everyone else walked away from.
Commercial risk
Bart Roszkowski
Co-CEO · commercial
- 5× founder, YC W21
- Vue Storefront / Alokai: scaled past $100M
Owns go-to-market, brand and capital
Science risk
Konrad Włodarczyk
Co-CEO · technology
- Invented the EntoPro process, holds the patents
- 6 years on the species-and-substrate problem
Owns the biology and the plant
The academic bench to back the science
Jagiellonian University, Collegium Medicum
Faculty of Pharmacy, Department of Plant and Medicinal Mushroom Biotechnology
Prof. Bożena Muszyńska · mushroom bioactives
AGH University
Faculty of Materials Engineering and Ceramics, Department of Analytical Chemistry and Biochemistry
Materials and process analytics
University of Agriculture in Kraków
Department of Animal Nutrition, Biotechnology and Fisheries
In vivo studies · Prof. Grzegorz Kulczycki, frass fertiliser
More healthy years,
grown in.
€500K
to close the current round.
Series A in 2027 is already half-underwritten by the EIC Fund.
It buys two things: the in-vivo data, and the capacity to scale.
Bart Roszkowski
co-CEO & co-founder
16 / 16